In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex/J&J: Pushing Big Pharma's Deal Flexibility to the Limit

Executive Summary

Vertex Pharmaceuticals deal with Johnson & Johnson for its Phase II hepatitis C protease inhibitor VX-950 underscore the significant potential for HCV protease inhibitors to alter the landscape of disease treatment and suggests pharmaceutical dealmakers will have to be ever more flexible to land biotech's best products.
Advertisement

Related Content

Vertex: Preparing to Go Commercial
In HCV, Protease Race Heats Up with Combo Therapy Looming
A Look Back at 2006: The Pipeline Challenge
Pharmaceutical Strategic Alliances 2006: Forcing Externalization at Big Pharma
European Consolidation: Serious Competition for Big Pharma?
The Rise of Regional Dealmaking
Regional EPO Deals: Large vs. Small Molecules
Deal Statistics Quarterly, Q2 2006
Hep C Development Dilemma: Big Money Now or Bigger Money Later?
Novartis and Idenix Pursue Interdependent Growth

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel